Ra Capital Management, L.P. Immuno Gen, Inc. Transaction History

Ra Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $296 Million - $711 Million	23,750,601 New	23,750,601 $704 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $155 Million - $218 Million	10,992,330 Added 471.78%	13,322,288 $211 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $73.2 Million - $391 Million	-19,524,000 Reduced 89.34%	2,329,958 $44 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $511,875 - $709,875	112,500 Added 0.52%	21,853,958 $108 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $6.39 Million - $11.2 Million	1,500,000 Added 7.41%	21,741,458 $103 Million

Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $8.66 Million - $13.7 Million	1,824,000 Added 9.9%	20,241,458 $150 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $42.1 Million - $87.1 Million	11,376,973 Added 161.59%	18,417,458 $119 Million
Q3 2020 Nov 16, 2020	BUY	$3.45 - $4.89 $24.3 Million - $34.4 Million	7,040,485 New	7,040,485 $25.3 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $17.2 Million - $27.6 Million	-5,166,303 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $11 Million - $35.1 Million	5,166,303 New	5,166,303 $17.6 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.